Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Veritas In Silico's Median PS Value or its related term are showing as below:
TSE:130A's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.63 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Veritas In Silico (TSE:130A) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Veritas In Silico's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
433.00
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veritas In Silico Median PS Value Related Terms
Veritas In Silico Median PS Value Historical Data
* Premium members only.
The historical data trend for Veritas In Silico's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:130A vs VRTX, REGN, MRNA: Median PS Value Comparison
For the Biotechnology subindustry, Veritas In Silico's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veritas In Silico Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veritas In Silico's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Veritas In Silico's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Veritas In Silico's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円13.075.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veritas In Silico (TSE:130A) has a Median PS Value of 円0.00 as of Sep. 02, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Veritas In Silico and its competitors. According to the industry distribution chart, Veritas In Silico ranks #999999 out of 282 companies in the Biotechnology industry.
Is Veritas In Silico's Median PS Value too high?
Veritas In Silico's current Median PS Value is 円0.00. Based on the distribution chart, Veritas In Silico ranks #999999 out of 282 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Veritas In Silico has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Veritas In Silico's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Veritas In Silico ranks #999999 out of 282 companies for Median PS Value. This places Veritas In Silico in the lower half of its industry. The industry median Median PS Value is 0.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 282 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Veritas In Silico and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veritas In Silico's current Median PS Value is 円0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veritas In Silico stock overvalued right now?
Based on GuruFocus' analysis, Veritas In Silico (TSE:130A) is currently considered Significantly Overvalued. The stock's GF Value™ is 円266.95, compared to a current price of 円433.00 — trading 62.2% above its estimated fair value. The current Median PS Value is 円0.00. Veritas In Silico's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Veritas In Silico (TSE:130A), the current Median PS Value is 円0.00 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veritas In Silico (TSE:130A) Overvalued in 2026?
Based on GuruFocus' analysis, Veritas In Silico stock appears to be overvalued.
The current stock price of 円433.00 is trading 62.2% above its estimated GF Value™ of 円266.95.
GuruFocus considers Veritas In Silico to be Significantly Overvalued.
Key valuation signals for TSE:130A:
Median PS Value: 円0.00
GF Value™: 円266.95 vs. price of 円433.00 (62.2% above fair value)
No single metric tells the full story. See the TSE:130A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.
28GF Score
Get the complete analysis for TSE:130A
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:130A has been successfully added to your 
